The FDA, in a regulatory first, approved a targeted therapy based on a basket study. The move, which expanded the indications for the BRAF inhibitor vemurafenib to include Erdheim–Chester disease, points to a new approval pathway for drugs that treat rare cancers.

中文翻译：

---

一揽子研究获得了罕见癌的批准

FDA首先通过篮筐研究批准了靶向治疗。此举扩大了BRAF抑制剂vemurafenib的适应症，使其包括Erdheim-Chester病，为治疗罕见癌症的药物开辟了新的批准途径。